Abstract
Background Austria, and particularly its westernmost federal state Vorarlberg, developed the highest COVID-19 incidence rate worldwide in November 2020. Health care workers (HCW) may be at higher risk of contracting the disease within the working environment and therefore the seroprevalence in this population is of particular interest. Here, we analyzed SARS-CoV-2-specific antibody response in Vorarlberg HCW in a prospective cohort study.
Methods A total of 395 HCW have been tested at three different time points for the prevalence of anti-SARS-CoV-2 IgG antibodies specific for NP and RBD. Enrollment started in June 2020 (t1), two months after the end of the first wave. Re-testing took place between October to November at the beginning of the second wave (t2), and again at the end of the second wave in January 2021(t3).
Results At t1, 3% of HCW showed a strong IgG-specific responses to either NP or RBD. At t2, the rate increased to 4%, and after the second wave in January 2021, 14% had a strong response, which was assessed to be stable for up to ten months. The amount of HCW with anti-SARS-CoV-2 IgG antibodies was 38% higher than the number of infections found by PCR.
Conclusion We found low numbers of SARS-CoV-2-seropositive HCW in a hotspot setting after the first wave but a massive increase during the second wave distinctly surpassing the number of infected HCW identified by PCR. Our findings, therefore, offer support for the routine application of serological testing in management of the ongoing COVID-19 pandemic.
Main summary A relatively low percentage of 3% SARS-CoV-2 seropositive HCW with strong IgG-specific antibody responses was found in the Austrian federal state Vorarlberg after the first wave increasing to 14% after the second massive wave lasting until January 2021.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
no clinical trial
Funding Statement
This work received a particular funding from the Austrian FFG (project number 880956).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Th study has been approved by the Ethics Committee of Vorarlberg (EK-2-4/2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding and disclosures This work received a particular funding from FFG (project number 880956). No potential conflicts of interest relevant to this article were reported by M.A., A.M., T.W., P.F., E.M.B., K.G., M.K., M.D., L.Sp., B.M., A.V., M.B., L.Se., J.J., H.D., A.La., and A.Le..
Data sharing statement The data that support the findings of this study are available from the corresponding author upon reasonable request.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
